Conventional phase II clinical trials evaluate the treatment effects under the assumption of patient homogeneity. However, due to inter-patient heterogeneity, the effect of a treatment may differ remarkably among subgroups of patients. Besides patient's individual characteristics such as age, gender, and biomarker status, a substantial amount of this heterogeneity could be due to the spatial variation across geographic regions because of unmeasured or unknown spatially varying environmental and social exposures. In this article, we propose a hierarchical Bayesian adaptive design for two-arm randomized phase II clinical trials that accounts for the spatial variation as well as patient's individual characteristics. We treat the treatment efficacy as an ordinal outcome and quantify the desirability of each possible category of the ordinal efficacy using a utility function. A cumulative probit mixed model is used to relate efficacy to patient-specific covariates and geographic region spatial effects. Spatial dependence between regions is induced through the conditional autoregressive priors on the spatial effects. A two-stage design is proposed to adaptively assign patients to desirable treatments according to each patient's spatial information and individual covariates and make treatment recommendations at the end of the trial based on the overall treatment effect. Simulation studies show that our proposed design has good operating characteristics and significantly outperforms an alternative phase II trial design that ignores the spatial variation.
Introduction
Increased understanding of the mechanistic heterogeneity of cancer has brought us to the era of precision medicine in clinical oncology. Under the paradigm of precision medicine, the effect of a treatment may differ significantly between patients due to inter-patient heterogeneity. Specifically, some drugs may benefit only 2% of the patients and there are even drugs that are harmful to certain ethnic groups. 1 Therefore, the conventional clinical trials that assume patient homogeneity are inappropriate to evaluate the individual level treatment effect. Indeed, to overcome the ''one-size-fits-all'' approach and to acknowledge patient heterogeneity, in January 2015, a new 215-million national Precision Medicine Initiative was launched. 2 Precision medicine provides an unbeatable opportunity for disease treatment and prevention that take into account each person's individual variability in genes, environment, and lifestyle.
Spatial variation is an important cause of patient heterogeneity in addition to clinical factors and biomarkers. Specifically, patients living in nearby areas are often exposed to similar physical and social environments such as air pollution, sunlight exposure, climatic factors, 3 and neighborhood conditions, 4,5 so they tend to have similar spatial effects. On the other hand, patients living in areas that are far apart can be exposed to very different environments, so the spatial variation may be substantial. Spatial pattern has been observed in survival rate and incidence of various diseases such as cancer. For example, mortality rate and incidence of lung cancer are known to be associated with various environmental risk factors and vary across geographic regions. 3, [6] [7] [8] Henderson et al. 9 demonstrated that there is good evidence that spatial dependence exists in survival rates of acute myeloid leukemia patients in northwest England. In a study of prevalence and morbidity of childhood asthma, Li and Ryan 10 showed that accounting for the spatial correlation improved the model. Therefore, it is reasonable to believe that the treatment effects may also vary substantially due to spatial variation, which is in turn determined by the living pattern of the patients. In fact, a reanalysis of the data from a clinical trial for the killed oral cholera vaccine did reveal that the spatial variation of the force of infection and vaccine coverage significantly affected the vaccine effectiveness. 11 Consequently, integrating the spatial variation into consideration, in addition to patient's individual covariates, may have the potential of improving clinical trial performance. Moreover, as the spatial effects are correlated between regions with the degree of correlation determined by the distance between regions, novel statistical methods are required to capture this spatial correlation.
Traditional phase II trials aim to examine the potential efficacy of a new treatment based on the assumption of patient homogeneity. [12] [13] [14] [15] [16] [17] However, in the presence of patient heterogeneity, this approach may draw incorrect conclusions. To account for patient heterogeneity, several phase II clinical trial designs have been proposed that take covariates such as patient prognostic covariates and disease subtypes into consideration. For example, Ibrahim et al. 18 proposed to incorporate historical control information to adjust for covariate effects in trend tests for binary data. Thall et al. 19 described an adaptive design that accommodates patient prognostic covariates as well as historical data in multicourse clinical trials. Thall et al. 20 presented a hierarchical Bayesian design for phase II clinical trials for diseases with multiple subtypes. Wathen et al. 21 proposed a design for single-arm phase II clinical trials that accounts for patient heterogeneity according to multiple prognostic subgroups. Recently, Guo and Yuan 22 proposed a personalized Bayesian dose-finding design that accounts for patient's individual characteristics. However, to the best of our knowledge, no phase II trial design has been developed to account for the spatial variation across geographic regions.
Our study was motivated by a phase II two-arm randomized clinical trial for non-small cell lung cancer patients, which is being conducted at the Indiana University Melvin and Bren Simon Cancer Center. A maximum of 100 patients will be enrolled and randomized to receive either the standard radiation therapy or a PI3K inhibitor plus radiation therapy. The outcome of interest is an ordinal variable indicating whether a patient reports partial or complete remission (PR/CR), stable disease (SD), or progressive disease (PD). The challenge of conducting this trial is that patients in the trial come from 12 different counties. Counties close to each other tend to share similar environments and living conditions while counties far apart could have quite distinct environments. The primary objective of the trial is to evaluate the efficacy of the experimental treatment relative to the standard treatment at a typical county, that is, a county with average environmental and social conditions.
In this article, we propose a Bayesian adaptive phase II clinical trial design that accommodates spatial variation and patient's individual characteristics. The objective of the proposed design is to determine whether the experimental treatment is superior compared with a standard treatment for each patient according to his/her individual covariates, while adjusting for spatial correlation. To account for the spatial variation, we introduce spatially structured random effects with a conditional autoregressive (CAR) prior distribution so that the random effects corresponding to geographic regions that are close to each other tend to have similar magnitude. These random effects can be interpreted as surrogates for unmeasured or unknown region-level exposure variables such as air pollution, which typically exhibit spatial pattern. The CAR prior is currently one of the most widely used models to incorporate spatial correlation. It is especially popular in Bayesian spatial survival analysis. [23] [24] [25] [26] [27] [28] In addition, rather than assuming a binary response outcome as in conventional phase II trials, we use ordinal efficacy outcomes. This is advantageous because the efficacy outcome is often scored as a multi-level ordinal variable such as PD, SD, PR, and CR in a real phase II trial, and dichotomizing the multi-level efficacy outcome into a binary variable loses information. 22, 29 This is especially true for molecularly targeted agents. The binary efficacy outcome in a traditional phase II trial typically defines CR/PR as a response, and PD/SD as a nonresponse. That is sensible for conventional cytotoxic agents that work by shrinking the tumor. However, due to a different functional mechanism, molecularly targeted agents function by stabilizing the tumor rather than shrinking it. So for these agents, SD is often regarded as a positive outcome because some targeted agents prolong survival by achieving durable SD without notable tumor progression. So although SD is less favorable than CR/PR, it should be distinguished from PD. Another commonly used measure, the clinical benefit rate, defines efficacy as SD/PR/CR, which does distinguish SD from PD but not from PR or CR. We use a utility function elicited from physicians to quantify the desirability of the treatments assuming an ordinal efficacy outcome. Based on the proposed Bayesian spatial model and utility function, we develop a two-stage phase II clinical trial design with a personalized randomization scheme to guide treatment assignment and selection. Based on the proposed design, both region-specific treatment effects and the overall treatment effect can be obtained. Final treatment recommendations are based on the overall treatment effect while treatment assignments for patients during the trial are based on region-specific treatment effects to maximize patient benefit.
The remainder of this article is organized as follows. In Section 2, we present the probability model for the ordinal efficacy outcome and the prior distribution specification. Section 3 describes a two-stage design to assign patients to treatment arms based on utility and make final recommendations. Section 4 examines the operating characteristics of the proposed design through simulation studies, and concluding remarks are provided in Section 5.
Method 2.1 Probability models
Consider a two-arm phase II clinical trial comparing a new treatment with a standard treatment. Let Y be the ordinal efficacy outcome with Y ¼ 1, 2, . . ., K representing increasingly desirable efficacy. Suppose the study area is subdivided into J geographic regions, which could be residential districts, clinical sites, cities, counties, states, etc. that are spatially arranged and potentially subject to spatial correlation. Let X ¼ ðX 1 , . . ., X q Þ 0 denote a vector of q patient-specific covariates such as age, gender, and biomarker status. Suppose during the trial, n j patients have been enrolled in geographic region j ð j ¼ 1, . . ., JÞ. The data from patient i ði ¼ 1, . . ., n j Þ in region j take the form ðY ij , X ij , Z ij Þ, where Z ij denotes the treatment indicator with Z ij ¼ 1 or 0 if he/she receives the experimental or the control arm, respectively. We model Y ij using the cumulative probit mixed regression model.
where 
k . This latent variable approach facilitates the Bayesian inference under standard priors. 30 
Prior specification
The region-specific random effects j 0 s can be interpreted as surrogates for unmeasured or unknown region-level covariates such as air pollution, neighborhood conditions, and social environments, which typically exhibit spatial pattern. If some of these region-level covariates could be measured, they should certainly be included in the regression model. However, these covariates are typically difficult or even impossible to measure. 10 Since neighboring regions tend to share similar environmental and social factors, it is reasonable to believe that random effects j 0 s corresponding to regions that are close to each other tend to have similar magnitude. Our approach aims to assign a prior distribution to h ¼ ð 1 , . . ., J Þ to achieve this spatial correlation.
We define two regions as neighbors if they share a common boundary. Different regions can have different numbers of neighbors. Consider the example illustrated in Figure 1 where there are 12 geographic regions. Region 1 has two neighbors, regions 2 and 5; region 2 has three neighbors, regions 1, 3, and 6; and region 6 has four neighbors, regions 2, 5, 7, and 10. We model the spatial correlation among regions by assigning h a Gaussian Markov random field prior distribution. We adopt the most popular intrinsic CAR models 31 with joint prior distribution of h given by
where j $ j 0 denotes that region j and region j 0 are neighbors and I is the number of ''islands'' (disconnected groups of regions) in the spatial structure. [32] [33] [34] I ¼ 1 defines a connected graph for the spatial structure.
The hyperparameter 4 0 controls the degree of smoothness. Small values of induce smoother realizations of the spatial effect. This prior is often denoted as h $ CARðÞ. Under this prior, the distribution of each element j for region j given all the other elements f j Ã , j Ã 6 ¼ jg depends only on its neighbors. To see this, the conditional distribution of j given all the other spatial effects follows a normal distribution
where j is the number of neighbors of region j. Since the conditional mean of j is the average of the effects of its neighbors, neighboring 0 j s will tend to have similar values. Also the conditional variance j is inversely proportional to the number of neighbors, which allows greater variability at regions with fewer neighbors and less variability at regions with more neighbors. This is appropriate for spatially correlated random effects because if a region has more neighbors, then there is more information about the value of its random effect from its neighbors. This CAR prior is improper because adding an arbitrary constant to each j will not change the joint density (3). To address this issue, we add the constraint P J j¼1 j ¼ 0 to guarantee identifiability and propriety of the prior distribution. 5, 35, 36 In the case of multiple ''islands'', the sum-to-zero constraint must be applied to each island separately. Now let us turn to the prior specification of the other parameters. We assign a conjugate Inverse Gamma prior to the hyperparameter . Since there may be little information about the spatial correlations between regions before we observe any data, we use a vague inverse gamma distribution $ Inv-Gammað0:01, 0:01Þ. To assign priors to the regression coefficients b ¼ ð 0 , 1 , b 2 , b 3 Þ, we follow a principle similar to that of Gelman et al. 37 The basic idea is that a typical change in a covariate is unlikely to lead to a dramatic change in the probability of the response variable. Under our probit model, a change of 2.5 on the probit scale moves a probability of efficacy in one category from 0.1 to 0.89. It is typically reasonable to assume that the effect of a covariate is unlikely to be more dramatic than that. This is particularly true for clinical trials where the target efficacy probability is rarely outside that range. We first standardize each covariate. Binary covariates are scaled to have a mean of 0 and to differ by 1 in the two categories, and other covariates are scaled to have a mean of 0 and a standard deviation of 0.5. Each element of b is assigned an independent normal prior distribution Nð0, 1:25 2 Þ. Under this prior, a change in a covariate from one standard deviation below the mean to one standard deviation above the mean will result in a change mostly within the range of ð0, 2:5Þ on the probit scale. Finally, each element of the boundaries c ¼ f k , k ¼ 2, . . ., K À 1g has the interpretation of the increment in intercept when adding additional categories in the cumulative probability in the probit model. Hence, based on the same consideration as for b, we assign each k a uniform prior distribution U(0,2.65) so that a priori, there is a 95% probability that k is between 0 and 2.5. In addition, we restrict the joint prior distribution of c on the subspace 2 5 Á Á Á 5 KÀ1 . For more details, please refer to Guo and Yuan. 22 where 1ðAÞ is the indicator function that equals 1 if event A is true and 0 otherwise, and ð ; , 2 Þ is the density of the normal distribution with mean and variance 2 . The joint posterior distribution of Â is pðÂjDÞ / LðÂ; DÞ pðhjÞ pðbÞ pðcÞ pðÞ ð 6Þ
Likelihood and posterior
We use the Gibbs sampler 38 to draw posterior inference. The posterior full conditional distributions for the model parameters are provided in the Supplementary Materials.
Accommodating for late-onset efficacy outcome
The proposed design described in the previous sections requires each patient to be completely followed before the next patient is treated. In practice, efficacy is evaluated over a predefined time window. Therefore, direct implement of the design may result in long trial durations due to the need to suspend patient accrual to wait for the outcomes of all previously treated patients to be fully determined before enrolling the next new patient. For example, suppose efficacy is evaluated up to 90 days post treatment and the expected patient accrual rate is three patients per month, then when a new patient enters the trial, patients who have been treated in the trial have not completed follow-up and thus their efficacy outcomes may not be available for fitting the model, resulting in censored observations. In addition, patients may drop out of the trial so follow-up is lost, or die of events unrelated to treatment. To address these issues caused by censored observations and missing data, we hereby extend the time-to-event continual reassessment method (TITE-CRM) 39 proposed by Cheung and Chappell to the ordinal efficacy case.
Suppose each patient is followed for a fixed period of time (0, ) to assess the efficacy of the treatment. The follow-up length is typically chosen so that if efficacy occurs, it would occur within (0, ). Taking the setting of our motivating trial, efficacy is an ordinal variable with categories PD, SD, and CR/PR. By the end of the followup , if neither PD nor CR/PR occurs, then we claim SD occurs. For patient i in region j, let u ij (0 5 u ij ) and 
where the weight functions
can be obtained from equation (1) . So the weighted likelihood based on the first n patients is
There are several options for the choice of the weight functions ! 1 ðu ij , Þ and ! 3 ðu ij , Þ as discussed in Cheung and Chappell. 39 A simple yet adequate choice is the linear weight function
That is, if a patient has developed PD or CR/PR, or has finished follow-up , the two weight functions
On the other hand, patients who have not developed PD or PR/CR are weighted by the amount of time they have been followed as the proportion of the follow-up window. This approach allows us to utilize both complete and incomplete information in fitting the model.
Decision criteria
Conventional phase II trials with binary efficacy outcomes base decision rules on response rates, e.g., the probability of tumor response. For an ordinal efficacy outcome with three or more categories, one practical approach is to dichotomize efficacy into a binary variable (e.g., response if CR or PR and nonresponse if PD or SD) and then use conventional decision rules. However, this approach suffers from several drawbacks mentioned earlier such as loss of information and ignorance of the mechanisms of the treatment, e.g., SD, although not as desirable as CR/PR, is often regarded as a favorable outcome as many treatments prolong survival without much tumor shrinkage. To get a more informative and meaningful summary of the ordinal outcome, we propose to make decisions based on a utility function elicited from physicians that characterizes the importance/desirability of each category of efficacy. To illustrate the utility function, we assume the efficacy outcome is categorized as a three-level ordinal variable, with Y ¼ 1, 2, 3 representing PD, SD, and PR/CR, respectively. We elicit from physicians three utility values ! 1 , ! 2 , ! 3 representing the desirability of the three categories Y ¼ 1, 2, 3, respectively. The three utilities must satisfy 0 ¼ ! 1 5 ! 2 5 ! 3 . One example is shown in Table 1 .
Constructing the utilities requires close collaboration between clinicians and statisticians, and should be customized for each trial to best reflect the clinical needs and practice. In our experience, the process of elicitation of utility values is quite natural and straightforward. For many trials, this may be done by simply explaining what the utilities represent to the clinicians during the design process and ask him/her to specify all utility values after fixing the scores for the best and worst outcomes. For our trial example, a convenient way of eliciting utilities that works well in practice is as follows: we fix the utility of the most desirable outcome (i.e., CR/PR) as ! 3 ¼ 100 and the utility of the least desirable outcome (i.e., PD) as ! 1 ¼ 0. Using these two boundary cases as reference, we then elicit the desirability of the other possible outcome (i.e., SD) from clinicians, which must be located between 0 and 100. In our example, the desirability of SD was determined to be ! 2 ¼ 50. For some targeted agents such as immunotherapeutic agents, patients who develop SD may achieve long-term survival and high quality of life. In such cases, desirability of SD, ! 2 , could be set to be higher than 50. On the other hand, for some agents for which SD implies short survival and/or poor quality of life, ! 2 can be set to be smaller than 50. This approach has been used in previous trial designs. 22, 29, [40] [41] [42] We define both the overall treatment effect and region-specific treatment effects. Based on the primary objective of our motivating trial to evaluate the efficacy of the experimental treatment relative to the standard treatment at a typical region (i.e., a region with average environmental and social conditions), we define the true overall treatment effect accordingly. For patients with covariates X, the true overall utility for treatment arm Z is defined as
where PrðY ¼ kjZ, XÞ is the probability at ¼ 0. Since P J j¼1 j ¼ 0, ¼ 0 represents the average spatial effect and so U true ðZ, XÞ is the true utility of treatment arm Z for patients with covariates X at a typical region, that is, one at the Table 1 . Utility for the ordinal efficacy with three levels.
center of the distribution of the spatial effects. The experimental treatment is considered promising compared with the standard treatment for patients with covariates X if the true utility increases by a certain percentage , that is
where is a minimum meaningful increment in utility and is pre-specified by the physicians. This is the treatment effect the clinicians are most likely interested in, i.e., the treatment effect occurring at a region that is ''just right'', neither below nor above average. 43 Likewise, to define the region-specific treatment effect for patients in region j with covariates X, the true regionspecific utility for treatment arm Z is defined as
The experimental arm is considered superior to the control arm for patients in region j with covariates X if the true region-specific utility increases by , that is
During the trial, given the interim data D n collected from n patients, let
denote the posterior estimate of the utility of treatment Z for patients with covariates X in region j, and let
denote the posterior estimate of the corresponding percentage of increase in utility, i.e., the region-specific treatment effect. Based on the Markov chain Monte Carlo (MCMC) samples of the parameters from their joint posterior distribution, the approximated posterior distribution of PrðY ¼ kjZ, X, j, D n Þ can be obtained from equation (1) . Specifically, for one MCMC sample of the parameters
Across all posterior samples of the parameters, the posterior distribution of PrðY ¼ kjZ, X, j, D n Þ can be approximated using the empirical distribution. Then we can get the (approximated) posterior distributions of U n ðZ, X, j Þ and Á n ðX, j Þ which are functions of PrðY ¼ kjZ, X, j, D n Þ. Treatment assignments for patients during the trial will be based on the posterior distributions of the region-specific treatment effects Á n ðX, j Þ to maximize patient benefit.
To estimate the overall treatment effect ÁðXÞ, we take the conditional broad inference approach for standard generalized linear mixed models (GLMMs)
where U n ðZ, XÞ ¼ P 3 k¼1 ! k PrðY ¼ kjZ, X, D n Þ denotes the posterior estimate of the utility of treatment Z for patients with covariates X at a region with spatial effect ¼ 0, based on data D n from the first n patients treated in the trial. Since ¼ 0 is the center of the spatial effect distribution, Á n ðXÞ is the estimated treatment effect for patients with covariates X at a typical region, i.e., a region with average spatial effect. The final treatment recommendations will be based on the posterior distributions of the overall treatment effects Á n ðXÞ.
For a phase II trial that accounts for spatial variation and patient heterogeneity, decision making is difficult at the beginning of the trial, because estimates of the efficacy probabilities based on a small number of patients are highly unstable in the presence of patient heterogeneity and spatial effects. To alleviate this issue, we propose a two-stage design. Let the maximum sample size be N. In stage I, we enroll N 1 patients and measure their covariates and residential regions. Patients in stage I are equally randomized to the control and the experimental arms. The purpose of this stage is to collect preliminary data to facilitate the model fitting in stage II. In stage II, we continue to enroll the remaining N 2 ¼ N À N 1 patients. Since there may be heterogeneity in treatment effect due to patient's individual covariates and spatial variation, we treat patients one by one, rather than as cohorts, in stage II and continuously update the posterior utilities to determine the treatment assignment for each patient. Specifically, assuming that n À 1 patients have been enrolled in the trial, we assign a treatment to the nth patient with covariates X in region j as follows:
(
In the design algorithm, 0 c 1 , c 2 1 are probability cutoffs with c 1 typically large (e.g., 0.9) and c 2 typically small (e.g., 0.1). These cutoffs will be tuned through simulation studies to achieve good design operating characteristics. Indeed, c 1 and c 2 can be viewed as counterparts of the early-stopping boundaries for superiority and futility, respectively, which are frequently used in conventional Bayesian adaptive designs. If PrðÁ nÀ1 ðX, j Þ 4 Þ 4 c 1 , then there is sufficient evidence that the experimental arm is superior to the control arm for the nth patient with covariates X in region j, so he/she should be assigned to the experimental arm. The interpretation of c 2 is similar.
After stage II is completed, final treatment recommendation is based on the overall treatment effect Á N ðXÞ. Specifically, for each set of covariates X, we claim the experimental treatment is promising if
and claim the experimental arm is not promising otherwise, where c is a probability cutoff to be tuned through simulation.
Simulation 4.1 Simulation setting
We conducted simulation studies to assess the operating characteristics of the proposed design. The maximum sample size was N ¼ 100, with stage I sample size N 1 ¼ 30 and stage II sample size N 2 ¼ 70. Let the covariate X be a binary biomarker with 50% positive marker prevalence. The efficacy outcome Y was taken to be a three-level ordinal variable. To mimic our motivating trial, we assumed 12 geographic regions representing districts/counties/ cities/states located as in Figure 1 . We used the utility function in Table 1 , i.e., ! 1 ¼ 0, ! 2 ¼ 50, and ! 3 ¼ 100. The minimum meaningful improvement of the utility was taken to be ¼ 30% so that the experimental agent was deemed promising relative to the standard treatment if the increase in utility exceeded 30%. We took the probability cutoffs c 1 ¼ 0:9, c 2 ¼ 0:1, and c ¼ 0.5, which yielded desirable operating characteristics. We implemented the design including the Gibbs sampler in R. In the MCMC procedure, after 1000 burn-in iterations, we ran 10,000 iterations from which every fifth sample was retained to reduce the autocorrelation in the Markov chain. Trace plots of the parameters indicated that the chain converged very fast. The R program can be obtained by contacting the corresponding author. We constructed eight scenarios to evaluate the performance of the proposed design. The true regression parameters for the eight scenarios are provided in Table S1 in the Supplementary Materials. Table 2 shows the true overall treatment effects under the eight scenarios, as well as the true efficacy probabilities and true utility for each biomarker subgroup under each treatment at ¼ 0. As shown by Table 2 , the eight scenarios were chosen to cover different cases of the overall treatment effects. In scenarios 1 and 2, the experimental treatment is not promising for marker negative group, and promising for marker positive group. In scenarios 3 and 4, the experimental treatment is promising for marker negative group, and not promising for marker positive group.
In scenarios 5 and 6, the experimental treatment is not promising for both marker groups; and in scenarios 7 and 8, the experimental treatment is promising for both marker groups. Note that the experimental arm was considered superior to the control arm if the utility of that arm was at least 30% higher than that of the control arm.
For each scenario, we considered two values of in the CAR model for h, and two situations in terms of the relative population of the 12 regions. was set to 2 or 10 to induce different degrees of spatial variations among the regions. In the first setting of relative population, we assumed all 12 regions had the same populations so the relative population was 1 : 1 : Á Á Á : 1. In the second setting, we assumed the relative population of the 12 regions was 1 : 2 : Á Á Á : 11 : 12 to evaluate the performance of the proposed design with unequal populations of the regions. The probability of sampling a patient from a particular region was proportional to its relative population. Spatially structured random vectors h were generated from the CAR model following the technique described in Norton and Niu. 5 Conditional on the regional random effects h, the efficacy outcomes were generated within each region under the probit model (1) .
To demonstrate the importance of accounting for the spatial variation in phase II trials, we compared our proposed design to a nonspatial design that incorporated the biomarker but ignored the spatial variation across the regions. That is, we used the same probit model (1), but with the spatial effects 0 j s dropped. To make a fair comparison, we used the same utility table and two-stage strategy for both designs.
Simulation results
Under each scenario, we simulated 500 trials for each combination of and relative population of the J regions. The percent of correct selection (PCS) of the true overall recommended treatment for the two biomarker subgroups is shown in Table 3 . Additionally, as we mentioned earlier, the proposed design can also report the region-specific treatment effects if the PI prefers. That is, in each simulated trial under any given scenario, each of the 24 combinations of region and biomarker has its own recommended treatment due to the spatial random The last column ''Á'' in each scenario shows the ''overall treatment effect'', which is the percentage of increase in utility for the experimental arm relative to the standard arm for each marker group at ¼ 0. If Á 4 0:3, the experimental arm is considered superior to the control. The bolded lines in each scenario represent the true recommended treatments for the two marker groups.
effects. Therefore, we report the simulation results for region-specific treatment effects in two ways. Table 4 shows the mean PCS of the true recommended treatment across the 24 combinations of biomarker and region under each scenario, and Figure 2 shows the PCS of the true recommended treatment for each of the 24 combinations under each scenario. The complete results of the PCS for the eight scenarios are provided in Tables S2 and S3 in the Supplementary Materials. The PCS measures the group ethics of the trial as it provides the performance of the designs to recommend treatments for future patients after the trial is completed. Table 5 shows the percentage of correct treatment assignment (PCTA) for the N 2 patients in stage II with AR. This provides a measure of the individual ethics of the trial as it evaluates the performance of the designs to assign appropriate treatments to the patients enrolled in the trial. The proposed spatial design outperformed the nonspatial design in terms of both PCS and PCTA according to our simulation results. For the overall treatment effect, Table 3 shows that the spatial design yielded better performance than the nonspatial design in most situations especially when ¼ 10 which induced greater spatial variation, and the nonspatial design resulted in very low PCS in certain scenarios. For example, in scenarios 7 and 8 with ¼ 10, the PCS for the two biomarker subgroups were between 0.606 and 0.746 under the spatial design and between 0.378 and 0.476 under the nonspatial design. In scenario 2 with ¼ 10, the PCS for biomarker subgroup X ¼ 1 were 0.674 and 0.632 under equal and unequal populations, respectively, under the spatial design, and only 0.432 and 0.442 under the nonspatial design. In scenario 4 with ¼ 10, the PCS for biomarker subgroup X ¼ 0 were 0.636 and 0.594 under equal and unequal populations, respectively, under the spatial design, and only 0.376 and 0.392 under the nonspatial design. For region-specific treatment effects, as shown in Table 4 , the proposed spatial design yielded consistently higher mean PCS than the nonspatial design across all the simulation settings. In particular, since a larger value of induces larger spatial variations, the advantage of our proposed spatial design was more pronounced under ¼ 10 than under ¼ 2. For instance, in scenario 1 with equal populations, the spatial design yielded 7.3% higher mean PCS than the nonspatial design when ¼ 2 (73.1% vs. 65.8%), and 21.3% higher mean PCS when ¼ 10 (77.8% vs. 56.5%). Figure 2 depicts the PCS stratified by the region and biomarker subgroup. As shown by Figure 2 , when ¼ 10, our proposed spatial design yielded consistently higher PCS than the nonspatial design across the 24 combinations of region and biomarker status. For example, in scenario 1, with ¼ 10 and equal populations, the proposed spatial model yielded 1%À15:8% and 27:4%À39% higher PCS than the nonspatial model across the 12 regions for marker negative and positive groups, respectively. In scenario 8, with ¼ 10 and unequal populations, the proposed design resulted in 20:6%À34:8% and 20:8%À29:6% higher PCS across all regions under marker negative and positive groups, respectively. When ¼ 2, the proposed design also gave higher PCS for almost all the combinations of region and marker group. For example, in scenarios 6, 7, and 8, PCS were consistently higher under the proposed design than under the nonspatial design for all combinations of region and biomarker status. In other scenarios, the proposed design yielded higher PCS for the majority of the 12 regions for each marker group. For example, in scenario 1, when the 12 regions had the same populations, the proposed design resulted in higher PCS for 11 out of the 12 regions for both marker groups, and slightly lower PCS for only one region, i.e., 62.4% vs. 64.8% for region 1 under marker negative group and 79% vs. 79.2% for region 6 under marker positive group. Table 5 reports the PCTA under the two designs. Again, the proposed spatial design yielded higher PCTA than the nonspatial design under all settings in all scenarios. For example, in scenario 1, the proposed design resulted in 6.1% and 16.5% higher PCTA when ¼ 2 and 10, respectively, under equal populations; and 5.1% and 16% higher PCTA, under unequal populations. To sum up, both the higher PCS and PCTA under the proposed design clearly demonstrate the importance of accounting for the spatial variation across geographic regions and the benefit of adopting the proposed spatial design.
Sensitivity analyses
We carried out sensitivity analyses to examine the robustness of our proposed spatial design to the prior distributions and the utility function. To simplify our presentation, only cases with equal populations were studied. In our original simulation studies, we used vague priors for all parameters. In the sensitivity studies, we let the prior distributions be even more non-informative. Specifically, we let the prior distribution of each element of b be Nð0, 5 2 Þ so the prior standard deviation was twice of the original standard deviation. And we assigned 2 a Unifð0, 5Þ prior distribution so the prior range was much wider than the original range. Under these new prior distributions, the results (see Figure 3 and Tables S5, S6 and S7 in the Supplementary Materials) are very similar to the original results reported in Figure 2 and Tables 3, 4 , and 5, suggesting that the proposed design is robust to the choice of the prior distributions.
To evaluate the sensitivity of the proposed design to the choice of the utility function, we considered two alternative utility functions (see Table S4 in the Supplementary Materials): the first (second) new utility gives higher (lower) desirability scores to the outcome Y ¼ 2. As shown in Figure 3 and Tables S5, S6 , and S7 in the Supplementary Materials, the results under the two alternative utilities are generally similar to those reported in Figure 2 and Tables 3, 4 , and 5. The complete table of PCS is given in the Supplementary Materials (Table S8) . We also evaluated the performance of the proposed spatial design when there is no spatial effect or correlation present in the data. Specifically, we generated data under scenarios 1-5 shown in Table S1 under two situations: (1) the spatial effects 0 j s were removed (i.e., set j ¼ 0 for all j) so there is no spatial variation, and (2) the spatial effects 0 j s were assumed to be i.i.d. N(0, 1) so there is no spatial dependence. In either case, the proposed spatial design yielded desirable operating characteristics (see Table S9 in the Supplementary Materials). In general, the CAR model should automatically determine the degree of spatial correlation. Small (large) values of induce smooth (near-independent) realization of the spatial effects.
We have assumed that the spatial regions are all connected (i.e., one ''island'' with I ¼ 1), but they do not have to be. Another concern that was pointed out by one reviewer is that some regions may have only a single patient in them. To assess the performance of our proposed spatial design in the case of multiple ''islands'' and single-patient in some regions, we conducted additional simulation studies with the spatial structure shown in Figure 4 , where there are three ''islands'' (i.e., I ¼ 3) and regions 1, 2, 5, 12 each has only one patient. The other regions are assumed to have equal populations. The proposed spatial model yielded reasonable operating characteristics in terms of PCS and PCTA for scenarios 1-5 in Table S1 (see Table S10 in the Supplementary Materials).
We have considered scenarios with one single binary biomarker. To further assess the operating characteristics of the proposed design, we generated six additional scenarios when there are two biomarkers. In scenarios 1-3, one biomarker is binary and one is continuous. We assume the binary biomarker has positive marker prevalence 0.5 and the continuous biomarker follows a normal distribution N(0, 16). In scenarios 4-6, both biomarkers are continuous, and we assume one follows a Gamma distribution Gamma(5, 0.5) and the other follows a normal distribution N(0, 16) so one biomarker can take only positive values and the other can take either positive or negative values. The true regression parameters for these six scenarios are provided in Table S11 in the Supplementary Materials.
Since each scenario involves continuous biomarkers, there are an infinite number of possible combinations of the values of the two biomarkers. To assess the PCS of the overall recommended treatment, we randomly pick 24 combinations of the two biomarkers in each simulated trial under each scenario and report the average PCS of the overall recommended treatment for 24 combinations across 1000 simulations in Table S12 in the Supplementary Materials. Likewise, for region-specific treatment effects, we randomly pick 24 combinations of biomarkers and region in each simulated trial and report the average PCS of the region-specific true recommended treatment for 24 combinations across 1000 simulations. Table S12 also shows the PCTA for the N 2 patients in stage II with AR. As can be seen, our proposed model yielded satisfactory operating characteristics in these scenarios.
Discussion
We have described a Bayesian adaptive phase II clinical trial design which accounts for the spatial variation as well as patient heterogeneity. Our design uses the cumulative probit regression to model the ordinal efficacy outcome and assigns an intrinsic CAR prior distribution to the region-specific random effects to achieve spatial dependence. We propose a two-stage design to assign patients to desirable treatments based on their spatial information and individual covariates and make the personalized treatment recommendation for future patients after the trial is completed. Simulation results show that our proposed design has desirable operating characteristics and outperforms an alternative design that ignores the spatial variation.
Our spatial design can be extended to phase I dose-finding designs, multi-arm phase II designs, and large-scale phase III confirmatory trials. In particular, we anticipate a substantial benefit of accounting for the spatial variation in phase III trials because the spatial effect is generally expected to be more significant in a large-scale phase III trial involving multicenter, or even multinational collaboration. Further research in this area is warranted.
In our simulation studies, we included a limited number of individual covariates in our proposed spatial design. It is conceptually easy to incorporate more covariates. However, due to the typical small or moderate sample sizes of phase II trials, we do not recommend to include too many covariates in the model. For example, with three biomarkers, there are nine regression parameters and an additional J þ 1 spatial parameters (i.e., j 's and ) to estimate, while the number of available observations was only N 1 ¼ 30 when the decision rules are first applied after the first stage of the trial. So the parameter estimates would be highly unstable especially at an earlier stage of the trial. For personalized dose-finding trials, Guo and Yuan 22 recommend the approach that directly includes both biomarkers and their interactions with the dose when there are 1 or 2 biomarkers, and some dimension reduction method such as the partial least squares when the number of biomarkers is three or more. Therefore, in general, we also recommend to use some dimension reduction technique when the number of biomarkers is three or more. Incorporating dimension reduction method in spatial clinical trial designs is our future work. Like many existing Bayesian adaptive clinical trial designs (e.g., Lee et al., 44 Yin et al., 45 Yuan et al. 46 ), our proposed design is based on AR. Compared with equal randomization (ER) that randomizes patients equally between treatments, AR uses the accumulating data to adapt the randomization probabilities so that on average more patients in the trial will receive the more effective treatment. Therefore, AR enhances the individual ethics of the trial and it is more desirable for patients enrolled in the trial. However, as a trade-off, AR sacrifices a little bit of power to detect a treatment effect. In addition, AR slightly increases the chance of a sample size imbalance in the wrong direction. To alleviate this problem, we equip the proposed design with a ''burn-in'' ER stage before applying AR, as suggested by Thall et al. 47 and Zang and Lee. 48 In this article, we model the spatial correlation using the CAR prior. As one reviewer pointed out, there are several alternatives to the CAR model, among which, the spatial Gaussian process model that usually pertains to point-referenced GIS coordinates 23, 25, 49 is one of the most popular versions. With the Gaussian process models, the degree of spatial correlation typically depends on the Euclidean distance between regions. In contrast to the CAR model that is defined on discretely indexed regions with a specific neighborhood structure, the Gaussian process models are indexed continuously throughout a space representing the geographic region being studied. One disadvantage of this approach, especially in the context of clinical trial designs, is that it is more computationally intensive than the CAR model. 23, 25 We choose to use the CAR model due to its simplicity and advantage in terms of computational speed. In a clinical trial with AR, computational speed is very important because the model parameters have to be updated after each patient's or each cohort of patients' outcomes have been observed. Implementing the Gaussian process models in spatial clinical trial designs is a future topic of interest.
Unlike conventional phase II clinical trials that typically implement futility stopping rules by assuming patient homogeneity, we do not implement such rules because the proposed design considers patient heterogeneity so the treatment effect varies with patients' individual characteristics. Specifically, a decision of futility for patients with a particular set of covariates cannot be generalized to the whole patient population. So it is generally implausible to implement formal futility stopping rules for personalized trials especially when some patient's characteristics are continuous so each patient is unique and the futility stopping boundary is different for each individual patient. One may be concerned that the lack of futility stopping considerations in a phase II oncology setting is ethically untenable. If this is a concern, ad hoc rules can be used, e.g., if a certain number, say 10, contiguous patients in stage II are assigned to the control arm, then we terminate the trial and conclude that the experimental treatment is futile. 22 In the special case that all patient's characteristics are categorical, futility stopping rules can be added for each subgroup of patients based on the overall treatment effect. For example, when there is one binary biomarker X ¼ 0/1 so there are two subgroups of patients, futility stopping rules can be implemented as follows:
. When n patients have been treated in the trial, if PrðÁ n ðXÞ 4 Þ 5 c 0 , we claim futility for patient subgroup X and stop enrolling patients with biomarker status X. This condition says that there is a small probability that the overall treatment effect is greater than for biomarker status X. If both subgroups X ¼ 0 and X ¼ 1 are early stopped, the trial is terminated. In this rule, c 0 is a probability cutoff to be tuned through simulation.
In this paper, we assume that the maximum sample size is fixed a priori, for example, because of a fixed budget or limited accrual. As one reviewer pointed out, in some clinical trials in which the sample size needs to be determined, we can formulate the problem in terms of an ''analysis objective'' and a ''design objective''. In the current context, the ''analysis objective'' would be to determine what data would lead to claiming superiority of the experimental treatment; and the ''design objective'' would be to select the sample size to achieve a desired level of assurance, which is analogous to the frequentist's power. This approach of separation of a design problem into an ''analysis objective'' and a ''design objective'' offers flexibility in the Bayesian inference in the sense that two sets of prior distributions can be used, one for the analysis stage and one for the design stage. This is particularly attractive when the pharmaceutical company which conducts the trial and external regulatory authorities who make decisions have different prior beliefs. 50 In our design, we base decisions on the posterior probabilities of clinically meaningful events (i.e., PrðÁ N ðXÞ 4 Þ and PrðÁ n ðX, j Þ 4 Þ), which is a commonly used method in Bayesian clinical trial designs. 42, 51, 52 The clinically meaningful events in our design are defined in terms of the utilities of the treatment arms.
